



PAD

EVAR

VALVES

SFA & BTK


VENOUS

HYPERTENSION

NEWSLETTER

LINC 2015 - Key Takeaways

- ▶ Drug-Coated Balloons dominated the conference
 - ▶ they are here to stay and expand their use
 - ▶ two DCBs were approved by FDA in 2014 - in October and December
 - ▶ deliver durable results to 12 months - at and above 80% patency for different DCBs
 - ▶ consensus - not all Drug-Coated Balloons are the same, but all of them are showing improved patency at 12 months over BMS
 - ▶ lesion preparation is important to allow for maximal therapeutic effect
 - ▶ Below the knee is getting more attention
 - ▶ still uncharted territory, where DCBs could bring a meaningful benefit
 - ▶ Are DCBs the solution for BTK?
 - ▶ How far down should the treatment be delivered?
 - ▶ In.Pact DEEP trial and its implications on the field
- ▶ Other drug delivery alternatives are coming in the forefront, e.g. Bullfrog Micro-Infusion Catheter
- ▶ Stenting has their place in SFA and POP lesions
 - ▶ Zilver PTX DES is becoming an important part of SFA care
 - ▶ new generation of bare-metal stents show lower TLR compared to older peripheral BMS - Abbott's SUPERA
- ▶ Atherectomy for calcified lesions: a new device was featured - Avinger's investigational Pantheris Catheter with




Drug-Coated Balloons
made the rounds!

- OCT visualization
- ▶ Alternative ways to address calcifications - Shockwave's Lithoplasty™ catheter breaks apart the calcification and could possibly allow for other therapies to work better
- ▶ EVAR
 - ▶ TriVascular
- ▶ Venous treatments
 - ▶ deep vein thrombosis - under-treated; dealing with thrombus as soon as it is formed
 - ▶ Veniti stent system
- ▶ Other topics discussed at the conference:
 - ▶ Hypertension
 - ▶ Renal denervation with radio-frequency, ultrasound (ReCor Medical) or other
 - ▶ The CVRx approach - active implantable electrically activating baroreceptors
 - ▶ TAVR - Lotus device used
 - ▶ Carotid artery treatments
 - ▶ challenging cases
 - ▶ stenting
 - ▶ embolic protection

Key Takeaways in Pictures



New Promising Technologies



PREFERRED CLINICAL RESEARCH, LLC™

Cost Effective and Timely Clinical Research

We are headquartered in Silicon Valley with operations in Eastern Europe, where clinical research is streamlined, with shorter approval timelines, state-of-the-art centers, high quality of data, fast enrollment and at a lower cost, never the less.